The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market encompasses a range of diagnostic procedures used to test donated blood for infections, diseases, and other health conditions before it is used for transfusions or other medical purposes. This market plays a critical role in ensuring the safety of blood supplies and preventing the transmission of infections such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible diseases. Driven by increasing demand for safe blood, rising awareness about blood-related disorders, and advancements in screening technologies such as nucleic acid testing and immunoassays, the Blood Screening Market continues to expand. Government initiatives, stringent regulations, and the growing need for early disease detection further contribute to the growth of this essential healthcare sector.
Continue reading for more details:
https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation
The blood screening market can be segmented by technology into nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing.
By product type, the market is segmented into reagents & kits, instruments, and software & services, with reagents & kits accounting for a large share.
The end-user segmentation includes blood banks, hospitals, diagnostic laboratories, and plasma centers.
By application, the market covers detection of HIV, hepatitis B & C, syphilis, malaria, and other transfusion-transmissible infections.
Automation and integration of AI-based screening platforms are emerging trends within the blood screening market, enhancing throughput and consistency.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Market Growth
The blood screening market is expanding rapidly due to the increasing demand for early disease detection and the rising prevalence of infectious diseases.
Growing awareness regarding blood safety and the importance of donor screening is significantly driving the blood screening market.
Technological advancements in molecular diagnostics and automation are contributing to enhanced accuracy and efficiency in the blood screening market.
Rising global healthcare spending and a surge in blood donations are supporting the long-term growth of the blood screening market.
The increase in government regulations and initiatives to improve transfusion safety is further accelerating the expansion of the blood screening market.
Restraining Factors
High cost of advanced screening technologies and instruments may limit the adoption in low- and middle-income regions.
The blood screening market faces challenges due to limited awareness and infrastructure in rural or underserved areas.
Stringent regulatory requirements and long approval timelines for new screening assays can hinder innovation and product availability.
The risk of false positives or false negatives in test results can affect the credibility and trust in the blood screening market.
Shortage of trained laboratory professionals to handle complex screening systems may restrict the growth of the blood screening market.
Regional Analysis
North America dominates the blood screening market, supported by advanced healthcare infrastructure, high awareness, and a strong regulatory framework.
Europe holds a significant share in the blood screening market, driven by mandatory blood testing policies and growing blood donation rates.
Asia Pacific is expected to witness the fastest growth in the blood screening market due to increasing healthcare investments, improving diagnostic capabilities, and rising disease prevalence.
Latin America presents emerging opportunities, though the blood screening market here is challenged by economic constraints and limited access to high-end screening technologies.
The Middle East & Africa region is gradually expanding, with increased governmental efforts to enhance blood safety and develop public health programs supporting growth in the blood screening market.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com